Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study

All NewsJuly 21, 2025

Alkermes’ alixorexton met key endpoints in a Phase 2 trial for narcolepsy type 1, showing strong efficacy and tolerability across all doses.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent